Last reviewed · How we verify
PF-04360365
At a glance
| Generic name | PF-04360365 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
- Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease (PHASE2)
- Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy (PHASE2)
- Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers (PHASE1)
- Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease (PHASE1)
- A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease (PHASE1)
- A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease (PHASE1)
- Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-04360365 CI brief — competitive landscape report
- PF-04360365 updates RSS · CI watch RSS
- Pfizer portfolio CI